| Methods |
Randomized
Double‐blind
Parallel‐group
Placebo‐controlled
Duration: 12 weeks |
| Participants |
Country: England
No. of centers: 1
Diagnosis: varying degrees of dementia
Diagnosis defined by: SCAG (Sandoz Clinical Assessment Geriatric Scale)
Total No. of patients: 37
Setting: inpatient
Age: Hydergine (range= 62‐93 years), Placebo (range= 68‐89 years)
Gender: 5 males, 32 females
Inclusion: Sandoz Clinical Assessment Geriatric > 2 points in 6 symptoms areas, and > 3 points in more than 2 designated symptoms.
Exclusion: psychosis, post‐traumatic brain disease, post‐infective brain disease, cerebral neoplasm, marked mental deterioration, psychotropic drugs, hypotensive drugs containing reserpine or with severe intercurrent illness. |
| Interventions |
Route: oral
Treatment: Hydergine 1.5 mg t.i.d.
Control: Placebo with multivitamin tablets and 600 mg of potassium t.i.d. |
| Outcomes |
SCAG (Sandoz Clinical Assessment Geriatric), other mental functioning tests, global rating |
| Notes |
No. excluded after randomization: Total=9, Treatment=5, Control=4.
No. not included in analysis at 6 weeks: Total=7, Treatment=3, Control=4.
No. not included in analysis at 12 weeks: Total=9, Treatment=5, Control=4. |
